Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gliatech Adcon

This article was originally published in The Gray Sheet

Executive Summary

All regulatory submissions related to the anti-adhesion technology over the next two years must be reviewed and certified by an independent auditor prior to submission to FDA under an agreement resolving issues raised in a December 2000 application integrity policy (AIP) letter from the agency. Gliatech plans to auction its Adcon assets as part of bankruptcy proceedings; the device is not available in the U.S. (1"The Gray Sheet" Sept. 30, 2002, In Brief)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT017302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel